Final research-target dose 2.4 mg + 2.4 mg weekly Titration length ~16 weeks Trial duration 68 weeks (REDEFINE 1 / REDEFINE 2) Route Subcutaneous, once weekly Compound Delivery: 2.4 mg / 2.4 mg Maintenance Pre-blended vials simplify weekly administration to a single injection but lock the ratio at 1:1
Aftercare Guidance: Youll receive advice on hydration, lifestyle, and potential synergistic treatments (like vitamin B12 or NAD+)
Zinc and magnesium are also important for immune function and reducing inflammatory responses, which can be beneficial for patients dealing with chronic inflammation associated with rheumatic conditions
Cardiovascular and Vascular Research Models Thymosin beta-4 and its fragments have been studied for their angiogenic and vasoprotective roles in laboratory models of cardiovascular stress
Fabio Hecht , Postdoctoral Scholar at the University of Rochester, shared on X : Preprint alert
Honest caveat: The vast majority of BPC-157 evidence is from animal studies